Poolbeg Pharma PLC has announced the grant of its first national patent covering the POLB-001 programme, which addresses cytokine release syndrome induced by cancer immunotherapy. The development represents a significant
All posts tagged in cancer immunotherapy
3Articles
Shares in Poolbeg Pharma PLC climbed as much as 10% during Tuesday morning trading following confirmation that the company has secured its first national patent grant for POLB 001, its
In a significant development in the fight against lung cancer, doctors have initiated the world’s first mRNA lung cancer vaccine trials in patients across seven countries. This pioneering jab, known
